Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of lanreotide 120 mg in China. Welcome to wholesale bulk high quality lanreotide 120 mg for sale here from our factory. Good service and reasonable price are available.
Lanreotide 120 mg is an artificially synthesized somatostatin analog that plays a crucial role in the treatment of acromegaly. As a long-acting growth hormone inhibitor octapeptide analogue, it effectively inhibits the secretion of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) by binding to somatostatin receptors (especially SSTR2 and SSTR5), thereby controlling the progression of acromegaly in patients.
Suitable for the treatment of acromegaly in various situations, including patients with abnormal growth hormone secretion after surgery and/or radiation therapy, as well as patients who are not suitable for surgery or radiation therapy. Its administration method is flexible, usually using deep intramuscular injection or subcutaneous injection.
Our Products Form
lanreotide COA
Acromegaly is a chronic progressive endocrine metabolic disease with insidious onset, mainly caused by excessive secretion of growth hormone (GH) due to anterior pituitary tumors, which can lead to multiple organ/system complications and seriously endanger the patient's life and health. Lanreotide 120 mg as artificially synthesized somatostatin receptor ligands (SRLs), they play a crucial role in the tratment of acromegaly.
As a first-line drug treatment option
For patients with acromegaly who cannot tolerate surgery, have residual lesions after surgery, or have difficulty meeting biochemical standards, it is an important tretment option. For example, some patients may find it difficult to tolerate surgery due to cardiovascular or respiratory complications, or may refuse surgery. In such cases, drug therapy may be the first choice; Some patients still have residual tumors after surgery, and their levels of GH and insulin-like growth factor-1 (IGF-1) have not been controlled, so they also need to receive tratment.
Information source:
Professor Zhu Huijuan from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, pointed out that surgical treament is currently the first-line tretment for acromegaly in clinical practice, but some patients rely on drug therapy for various reasons. Among them, synthetic SRLs are the first-line drugs for treating acromegaly, and as one of the representative drugs of SRLs, they have advantages in tretment.
Clinical validation:
Multiple Phase III clinical studies have confirmed its efficacy and safety. The IPSEN-081 study evaluated its efficacy and safety in patients with untreated or uncontrolled acromegaly, and the results showed that after 12 weeks of tretment, 26% of patients' IGF-1 levels returned to normal; After 48 weeks, 85% of patients had GH levels ≤ 2.5 μ g/L, and 43% of patients had normal IGF-1 levels. The PRIMARYS study evaluated its efficacy in reducing tumor volume in newly treated patients with GH secreting pituitary adenomas.
After 12 weeks of tratment, 54.1% of patients had a tumor volume reduction of ≥ 20%, and the trend of tumor reduction continued until the end of the study. After 48 weeks, 62.9% of patients had a tumor volume reduction of ≥ 20%, and GH and/or IGF-1 levels significantly decreased from week 12. The proportion of patients who met the criteria increased over time.
Realize biochemical control
Application Status
This substance can effectively help patients with acromegaly achieve biochemical control and reduce GH and IGF-1 levels. In real-world clinical practice in China, numerous patients have achieved effective control of GH and IGF-1 levels through the use of lanreotide 120 mg. For example, a study included 129 patients (with an average age of 43.3 years and a female proportion of 58.1%) who received at least one tratment. By the 12th month of tretment, 102 patients completed the study and collected GH and IGF-1 data from the 12th month. Among them, 19.6% (20/102) of patients achieved complete biochemical control, 11.8% (12/102) of patients achieved GH<1 μ g/L and normal IGF-1, and 34.3% (35/102) of patients achieved GH ≤ 2.5 μ g/L and IGF-1 ≤ 1.3 × ULN. Fasting GH levels decreased from baseline 23.17 μ g/L to 8.33 μ g/L, and IGF-1 decreased from 1.974 × ULN to 1.332 × ULN.
Source of information:
The relevant research data comes from clinical practice in the real world of China, with the participation of institutions such as Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences, providing important evidence for the biochemical control effect of lanrelitide in the tratment of acromegaly.
Clinical validation
In addition to the aforementioned real-world studies in China, multiple international studies have also validated its biochemical control effects. The SODA study is a large-scale multicenter real-world study conducted in the United States to investigate the efficacy of lanrelitide ATG in treating acromegaly. During the one-year tratment, 72% of the 87 eligible patients had IGF-1 levels below the upper limit of normal;
Among the 50 patients eligible for analysis, 60% had fasting GH levels<1 µ g/mL, and 80% had fasting GH levels ≤ 2.5 µ g/mL. During the 2-year tretment, the proportion of patients with GH levels ≤ 2.5 µ g/L at 12 months (M12) and 24 months (M24) was 83.3% and 80.0%, respectively; The proportion of patients with M12 and M24 GH levels<1.0 µ g/L was 61.7% and 61.4%, respectively; The proportions of M12 and M24 with normal levels of IGF-1 and GH levels ≤ 2.5 µ g/L were 65.0% and 54.8%, respectively; The proportion of M12 and M24 patients with normal IGF-1 levels and GH levels ≤ 1.0 µ g/L was 51.7% and 42.9%, respectively.
Improve clinical symptoms
It can significantly improve the clinical symptoms of patients with acromegaly. The typical symptoms of acromegaly include facial changes, enlarged fingers, thickened skin, headaches, changes in vision, joint pain, soft tissue swelling, excessive sweating, etc. After tratment, these symptoms can be relieved to varying degrees. For example, in real-world studies in China, the proportion of patients reporting any symptoms related to acromegaly decreased from 87.5% at baseline to 77.9% (-9.6%) at 12 months, with the most significant improvement in headache (-17.1%), followed by soft tissue swelling (-8.1%) and excessive sweating (-6.5%).
Source of information:
The real-world research in China provides direct evidence for the improvement of clinical symptoms in patients with acromegaly by lanrelitide, which records in detail the changes in symptoms before and after tratment.
clinical validation:
The SODA study also confirmed its effect on improving symptoms. During a 2-year follow-up, the patient's symptoms stabilized or improved at M24. This indicates that lanrelitide can continuously improve patients' clinical symptoms and enhance their quality of life during long-term treatment.
Improve the quality of life
It can improve the quality of life of patients with acromegaly by improving biochemical indicators and clinical symptoms, which can enhance their psychological and physical health. Patients with acromegaly often experience psychological pressure and their quality of life is severely affected due to changes in facial appearance, physical discomfort, and other reasons. After tretment with lanreotide 120 mg, patients' quality of life scale scores will significantly improve.
Source of information:
A real-world study in China used the AcroQoL scale to assess the quality of life of patients with acromegaly. The results showed that the overall AcroQoL score increased by an average of 5.7 points compared to baseline (95% CI: 3.1, 8.2), and there was consistent improvement in both psychological and physical health dimensions.
Clinical validation
The SODA study also focused on the quality of life of patients, evaluating the impact on their lives through methods such as patient questionnaire surveys during the 1-year and 2-year tratment periods. The results showed that the substance has good safety and is more convenient to use, with high patient acceptance, which indirectly reflects the positive impact of the drug on patients' quality of life.
During the 2-year tratment, for patients who received long-acting octreotide before enrollment (n=100), a higher proportion (81.0%) considered ATG to be "very" or "relatively" convenient compared to the previous regimen after switching to ATG tretment; Compared with previous studies of the same type, patients in M12 (77.4%) and M24 (80.0%) have a higher proportion of patients who evaluate the convenience of Lanrui Peptide ATG injection. Convenient tratment methods help improve patients' quality of life.
Hot Tags: lanreotide 120 mg, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, 6 methylergoline 8beta carboxylic Acid CAS 5878 43 3, Camptothecin Powder CAS 7689 03 4, Clascoterone Powder CAS 19608 29 8, D Pantothenic Acid Hemicalcium Salt CAS 137 08 6, Loperamide Hydrochloride Powder CAS 34552 83 5, Paliperidone powder